What Is Uroguanylin? Definition and What Research Reports

Definition

Uroguanylin is a small, naturally occurring peptide hormone belonging to the guanylin peptide family. It is synthesised mainly by epithelial cells of the gastrointestinal tract, stored and secreted as a larger inactive precursor called prouroguanylin, and processed to its active form, where it binds and activates the membrane receptor guanylate cyclase-C (GC-C). Receptor activation raises intracellular cyclic GMP, a second messenger linked in the published literature to intestinal ion and fluid transport. Because uroguanylin appears in plasma and urine as well as the gut lumen, it has been described in research as a candidate intestinal–renal signalling molecule. This page is for educational purposes only and is not medical advice; consult a licensed physician for any questions about health, medication or laboratory testing.

What Class of Molecule It Is and Where It Comes From

Uroguanylin is a peptide — not a steroid, not a small-molecule drug — and it is classed as an endogenous hormone rather than a synthetic research compound. Its closest relative is guanylin, a second GC-C-activating peptide with an overlapping but distinct distribution along the gastrointestinal tract. Researchers mapped where these two peptides are made using mRNA localisation in human and rat duodenal and colonic mucosa, reporting cell-type-specific expression patterns across those regions (PMID 27044258).

In review form, the guanylin–uroguanylin pair has been described as a “nexus” in intestinal electrolyte and fluid homeostasis, with the review summarising GC-C/cyclic GMP signalling as the shared pathway through which both peptides influence epithelial transport (PMID 35158329). Not every reported action of uroguanylin has been attributed to that receptor, however: one laboratory study reported that uroguanylin increased calcium concentration in astrocytes through a guanylate cyclase-C-independent signalling pathway (PMID 34212562).

How the Term Is Used in Peptide Research

In the literature, “uroguanylin” is used in several distinct senses, and the distinctions matter when reading an abstract:

• The mature hormone — the short active peptide that binds GC-C, typically measured in tissue or administered in animal experiments.
• Prouroguanylin — the circulating precursor, which is what most human endocrine studies actually quantify in plasma, often before and after a meal stimulus.
• A biomarker — plasma or tissue levels used as a readout of gut endocrine function in conditions such as constipation or obesity.
• A template for analogs — synthetic GC-C agonists modelled on the uroguanylin sequence. A computational modelling paper examined plecanatide, described as a uroguanylin analog, in the context of therapeutically targeting guanylate cyclase-C (PMID 28357122).

Uroguanylin itself is an endogenous hormone and a subject of laboratory and clinical investigation; it is not marketed as a consumer product, and the analog literature concerns prescription pharmaceutical development rather than self-administered peptides.

What the Published Literature Reports

Gut fluid and electrolyte handling

The review of guanylin and uroguanylin framed both peptides as regulators of intestinal electrolyte and fluid balance acting through GC-C, and discussed that axis as a target of pharmacological interest (PMID 35158329). The localisation work in human and rat duodenum and colon provided the anatomical basis for that model by identifying the mucosal cells expressing guanylin and uroguanylin mRNA (PMID 27044258).

Energy balance, leptin and food preference

A 2019 mouse study reported that uroguanylin improved leptin responsiveness in diet-induced obese mice (PMID 30935076). Earlier rodent work reported that uroguanylin levels in intestine and plasma were regulated by nutritional status in a leptin-dependent manner, linking the peptide to feeding state rather than treating it as a static gut product (PMID 25743370). A narrative review then positioned uroguanylin as “a new actor in the energy balance movie,” summarising gut-to-brain signalling hypotheses drawn from that experimental literature (PMID 29203517).

Human observational work extended the theme to taste and preference: researchers reported high plasma and lingual uroguanylin as potential contributors to changes in food preference after sleeve gastrectomy (PMID 34990711).

Bariatric surgery and prouroguanylin responses

Because prouroguanylin is meal-responsive, several studies used it as an endocrine readout around metabolic surgery. One study examined perioperative changes in the prouroguanylin hormone response in severely obese subjects after bariatric surgery (PMID 31472974). In an animal model, the study of sleeve gastrectomy in diet-induced obese hypertensive rats reported blood pressure reduction after surgery and discussed a potential role of prouroguanylin in that effect (PMID 41305631).

Constipation

In a clinical study of gastrointestinal function, researchers reported blunted evoked prouroguanylin endocrine secretion in chronic constipation compared with control conditions, supporting the use of the precursor as a measurable gut hormone signal (PMID 31318728).

Sodium excretion and blood pressure

A 2022 study reported a synergistic effect of uroguanylin and D₁ dopamine receptors on sodium excretion in hypertension, describing an interaction between gut-derived and renal dopaminergic signalling (PMID 35229618). That line of work is part of why uroguanylin is sometimes described in reviews as an intestinal natriuretic hormone.

Research Contexts at a Glance

Adverse Events: What Studies Report

The verified papers summarised on this page were primarily mechanistic, biomarker or modelling studies rather than safety trials, and their titles and abstracts did not centre on adverse-event reporting for administered uroguanylin. The rodent experiments reported physiological endpoints such as leptin responsiveness (PMID 30935076) and blood pressure changes after sleeve gastrectomy with a discussed role for prouroguanylin (PMID 41305631), while the human work measured endogenous hormone levels rather than administering the peptide (PMID 31318728). No tolerability conclusions about human uroguanylin administration can be drawn from this set of references.

Reading Notes

• Species matters. Several energy-balance findings came from mice or rats (PMID 30935076, PMID 25743370), and rodent results do not automatically translate to humans.
• Hormone versus precursor. Human studies frequently reported prouroguanylin, the circulating precursor, rather than the mature peptide (PMID 31472974).
• Association versus causation. Post-surgical observations described associations, such as high plasma and lingual uroguanylin alongside altered food preference (PMID 34990711).

References

• Guanylin and uroguanylin: a promising nexus in intestinal electrolyte and fluid homeostasis (Journal of Physiology and Pharmacology, 2021)
• Cellular localization of guanylin and uroguanylin mRNAs in human and rat duodenal and colonic mucosa (Cell and Tissue Research, 2016)
• Uroguanylin Improves Leptin Responsiveness in Diet-Induced Obese Mice (Nutrients, 2019)
• Uroguanylin levels in intestine and plasma are regulated by nutritional status in a leptin-dependent manner (European Journal of Nutrition, 2016)
• Uroguanylin: a new actor in the energy balance movie (Journal of Molecular Endocrinology, 2018)
• Blunted Evoked Prouroguanylin Endocrine Secretion in Chronic Constipation (Clinical and Translational Gastroenterology, 2019)
• Perioperative changes in prouroguanylin hormone response in severely obese subjects after bariatric surgery (Surgery, 2019)
• High plasma and lingual uroguanylin as potential contributors to changes in food preference after sleeve gastrectomy (Metabolism, 2022)
• Effects of Sleeve Gastrectomy on Blood Pressure Reduction in Diet-Induced Obese Hypertensive Rats: A Potential Role of Prouroguanylin (Nutrients, 2025)
• Synergistic Effect of Uroguanylin and D1 Dopamine Receptors on Sodium Excretion in Hypertension (Journal of the American Heart Association, 2022)
• Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog (Pharmacology Research & Perspectives, 2017)
• Uroguanylin increases Ca2+ concentration in astrocytes via guanylate cyclase C-independent signaling pathway (Croatian Medical Journal, 2021)